| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 4373 | 2018 |
| Fundamental mechanisms of immune checkpoint blockade therapy SC Wei, CR Duffy, JP Allison Cancer discovery 8 (9), 1069-1086, 2018 | 2928 | 2018 |
| Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade SC Wei, JH Levine, AP Cogdill, Y Zhao, NAAS Anang, MC Andrews, ... Cell 170 (6), 1120-1133. e17, 2017 | 1280 | 2017 |
| Matrix stiffness drives epithelial–mesenchymal transition and tumour metastasis through a TWIST1–G3BP2 mechanotransduction pathway SC Wei, L Fattet, JH Tsai, Y Guo, VH Pai, HE Majeski, AC Chen, RL Sah, ... Nature cell biology 17 (5), 678-688, 2015 | 973 | 2015 |
| Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies SC Wei, NAAS Anang, R Sharma, MC Andrews, A Reuben, JH Levine, ... Proceedings of the National Academy of Sciences 116 (45), 22699-22709, 2019 | 327 | 2019 |
| Forcing through tumor metastasis: the interplay between tissue rigidity and epithelial–mesenchymal transition SC Wei, J Yang Trends in cell biology 26 (2), 111-120, 2016 | 226 | 2016 |
| A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention SC Wei, WC Meijers, ML Axelrod, NAAS Anang, EM Screever, ... Cancer discovery 11 (3), 614-625, 2021 | 213 | 2021 |
| T cells specific for α-myosin drive immunotherapy-related myocarditis ML Axelrod, WC Meijers, EM Screever, J Qin, MG Carroll, X Sun, ... Nature 611 (7937), 818-826, 2022 | 194 | 2022 |
| Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer Y Ma, J Li, H Wang, Y Chiu, CV Kingsley, D Fry, SN Delaney, SC Wei, ... Gastroenterology 159 (1), 306-319. e12, 2020 | 125 | 2020 |
| Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States SC Wei, R Sharma, NAAS Anang, JH Levine, Y Zhao, JJ Mancuso, ... Immunity 50 (4), P1084-1098.E10, 2019 | 103 | 2019 |
| Stress tolerance to stress escape in plants: role of the OXS2 zinc‐finger transcription factor family R Blanvillain, S Wei, P Wei, JH Kim, DW Ow The EMBO journal 30 (18), 3812-3822, 2011 | 103 | 2011 |
| Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018; 8 (9): 1069–1086. doi: 10.1158/2159-8290 SC Wei, CR Duffy, JP Allison CD-18-0367, 0 | 73 | |
| Systematic analysis of rat 12/15-lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in inflammatory hyperalgesia AM Gregus, DS Dumlao, SC Wei, PC Norris, LC Catella, FG Meyerstein, ... The FASEB Journal 27 (5), 1939, 2013 | 52 | 2013 |
| Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8: 1069–1086 SC Wei, CR Duffy, JP Allison | 51 | 2018 |
| The forces behind EMT and tumor metastasis SC Wei, L Fattet, J Yang Cell Cycle 14 (15), 2387-2388, 2015 | 40 | 2015 |
| Inhibition of spinal 15-LOX-1 attenuates TLR4-dependent, nonsteroidal anti-inflammatory drug–unresponsive hyperalgesia in male rats AM Gregus, MW Buczynski, DS Dumlao, PC Norris, G Rai, A Simeonov, ... Pain 159 (12), 2620-2629, 2018 | 15 | 2018 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 13 | 2016 |
| Checkpoint Blockade+ Chemotherapy: the Right Combination for AML? SC Wei, JJ Mancuso, N Daver, JP Allison Blood cancer discovery 2 (6), 551-554, 2021 | 2 | 2021 |
| Identification of a Guide RNA Targeting an Ultraconserved Element for Evaluation of Cas9 Genome Editors Across Mammalian Species BG Gowen, P Khekare, SR McCawley, K Melton, C Soares, J Chan, ... The CRISPR Journal 7 (6), 306-309, 2024 | 1 | 2024 |
| Diversity and composition of the gut microbiome influences responses to anti-PD1-therapy through beneficial changes in innate and adaptive immunity V Gopalakrishnan, C Spencer, L Nezi, A Reuben, M Andrews, T Karpinets, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017 | 1 | 2017 |
